Micrograph of serous carcinoma. Credit: Ed Uthman.

MaxCyte has dosed the first patient in a Phase I clinical trial to evaluate the safety and effectiveness of intraperitoneal infusions of MCY-M11 for the treatment of advanced ovarian cancer and peritoneal mesothelioma.

The multi-centre, non-randomised, open-label, dose-escalation trial intends to enrol around 15 subjects across two clinical sites in the US, including National Cancer Institute at National Institutes of Health (NIH) and Washington University.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It will include women with platinum-resistant, high-grade serous adenocarcinoma of the ovary, primary peritoneum or fallopian tube, or subjects with advanced peritoneal mesothelioma with recurrence after prior chemotherapy.

The trial will feature four experimental cohorts with three to six subjects in each of the cohorts.

“In recent years we have seen tremendous progress in the treatment of some types of cancer, but there remains a significant need to explore novel treatments that may benefit patients.”

The primary objective of the trial is the incidence and severity of adverse events as measured by Common Terminology Criteria for Adverse Events v.5.0 (CTCAE v.5.0).

The trial’s secondary objectives include response evaluation criteria in solid tumours (RECIST) and immune-related response evaluation criteria in solid tumours (irRECIST).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

MaxCyte chief medical officer Claudio Dansky Ullmann said: “In recent years we have seen tremendous progress in the treatment of some types of cancer, but there remains a significant need to explore novel treatments that may benefit patients.

“Individuals with advanced and relapsed ovarian cancer or peritoneal mesothelioma have limited effective therapeutic options today. MCY-M11 is an exciting new approach with the potential to improve outcomes for these patients.”

MCY-M11 is currently being studied as a chimeric antigen receptor (CAR) therapeutic product candidate.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact